Evidence map›Paper›PMID 35007288›Full record

ArticlePLoS pathogens2022

Fasciola hepatica is refractory to complement killing by preventing attachment of mannose binding lectin (MBL) and inhibiting MBL-associated serine proteases (MASPs) with serpins.

Carolina De Marco Verissimo, Heather L Jewhurst, József Dobó, Péter Gál, John P Dalton, Krystyna Cwiklinski

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Deciphering theBiomolecules · 2025
    Review
  5. Pathogens (Basel, Switzerland) · 2025
    Article
  6. Article
  7. Article
  8. An Update on the Pathogenesis of Fascioliasis: What Do We Know?Research and reports in tropical medicine · 2024
    Review
  9. Article
  10. Molecular Characterization of the Interplay betweenInternational journal of molecular sciences · 2023
    Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Carolina De Marco VerissimoCentre for One Health and Ryan Institute, School of Natural Sciences, National University of Ireland Galway, Galway, Ireland.ORCID 0000-0003-1762-6387
Heather L JewhurstCentre for One Health and Ryan Institute, School of Natural Sciences, National University of Ireland Galway, Galway, Ireland.
József DobóInstitute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary.ORCID 0000-0001-9187-8502
Péter GálInstitute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary.ORCID 0000-0001-8987-2080
John P DaltonCentre for One Health and Ryan Institute, School of Natural Sciences, National University of Ireland Galway, Galway, Ireland.ORCID 0000-0003-3829-9186
Krystyna CwiklinskiCentre for One Health and Ryan Institute, School of Natural Sciences, National University of Ireland Galway, Galway, Ireland.ORCID 0000-0001-5577-2735
Ollscoil na Gaillimhe – University of Galway · IEInstitute of Molecular Life Sciences · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The complement system is a first-line innate host immune defence against invading pathogens. It is activated via three pathways, termed Classical, Lectin and Alternative, which are mediated by antibodies, carbohydrate arrays or microbial liposaccharides, respectively. The three complement pathways converge in the formation of C3-convertase followed by the assembly of a lethal pore-like structure, the membrane attack complex (MAC), on the pathogen surface. We found that the infectious stage of the helminth parasite Fasciola hepatica, the newly excysted juvenile (NEJ), is resistant to the damaging effects of complement. Despite being coated with mannosylated proteins, the main initiator of the Lectin pathway, the mannose binding lectin (MBL), does not bind to the surface of live NEJ. In addition, we found that recombinantly expressed serine protease inhibitors secreted by NEJ (rFhSrp1 and rFhSrp2) selectively prevent activation of the complement via the Lectin pathway. Our experiments demonstrate that rFhSrp1 and rFhSrp2 inhibit native and recombinant MBL-associated serine proteases (MASPs), impairing the primary step that mediates C3b and C4b deposition on the NEJ surface. Indeed, immunofluorescence studies show that MBL, C3b, C4b or MAC are not deposited on the surface of NEJ incubated in normal human serum. Taken together, our findings uncover new means by which a helminth parasite prevents the activation of the Lectin complement pathway to become refractory to killing via this host response, in spite of presenting an assortment of glycans on their surface.

Indexed as

AnimalsComplement System ProteinsFasciola hepaticaHelminth ProteinsHumansImmunity, InnateMannose-Binding LectinMannose-Binding Protein-Associated Serine ProteasesSerpinsComplement System ProteinsHelminth ProteinsMannose-Binding LectinMannose-Binding Protein-Associated Serine ProteasesSerpins

Identifiers

PMID35007288
PMCPMC8782513
OpenAlexW4205781499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.